Back HIV/AIDS HIV/AIDS Topics HIV Prevention

Experimental HIV Vaccine to Enter Large Clinical Trial in South Africa

An investigational vaccine that showed promise in an earlier study will advance to a large-scale efficacy trial at 15 sites in South Africa, the U.S. National Institutes of Health (NIH) announced on May 18, marking HIV Vaccine Awareness Day. The new trial, HVTN 702, designed to determine if the vaccine is safe, well-tolerated, and effective at preventing HIV infection, is due to start this November, with results expected in 4 years.

alt

Read more:

U.S. Government Updates Guidelines for HIV Post-Exposure Prophylaxis

The U.S. Centers for Disease Control and Prevention (CDC) and Department of Health and Human Services (DHHS) in April issued their latest guidelines for non-occupational post-exposure prophylaxis (PEP) for people potentially exposed to HIV through sex or shared injection equipment. The update includes new antiretrovirals approved since the last revision, with the preferred regimen now being raltegravir (Isentress) or dolutegravir (Tivicay) plus tenofovir/emtricitabine (the drugs in Truvada).

alt

Read more:

Study Sheds Light on Why Women Need More Truvada for HIV PrEP

Tenofovir and emtricitabine -- the drugs in the Truvada combination pill used for HIV pre-exposure prophylaxis (PrEP) -- reach higher levels in rectal compared with female genital tract tissue, and the rectum also contains fewer of the natural DNA building blocks that compete with the drugs, according to research published in the February 24 advance online edition of the Journal of Infectious Diseases.

alt

Read more:

BHIVA 2016: Which Men Stand to Benefit Most from PrEP?

New data from the PROUD pre-exposure prophylaxis (PrEP) study have identified the characteristics of the gay and other men who have sex with men who are most likely to benefit from PrEP, according to findings reported at the recent conference of the British HIV Association (BHIVA) in Manchester. Gay men with rectal sexually transmitted infections (STIs) and those who had unprotected receptive anal sex with more partners were most likely to benefit from PrEP.

alt

Read more:

England's PrEP Policy in Disarray After National Health Service Turnaround

Activists, individuals at risk of HIV, and clinicians have reacted with anger to an official U-turn on provision of HIV pre-exposure prophylaxis (PrEP) in England, where National Health Service (NHS) officials have refused to allow a draft policy on PrEP to go forward for further consideration. "By denying full availability of PrEP we are failing those who are at risk of HIV," commented Ian Green of Terrence Higgins Trust, a leading U.K. HIV/AIDS organization. "PrEP has already been approved in the U.S., Kenya, South Africa, Israel, Canada, and France. And yet, our own government refuses to take responsibility for PrEP."

alt

Read more: